National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine
A multipeptide vaccine consisting of five peptides derived from the bcr-abl p210-b3a2 breakpoint fusion protein with potential antineoplastic activity. Vaccination with bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl p210-b3a2 breakpoint fusion protein. In chronic myelogenous leukemia (CML), fusion genes typically result from the fusion of either bcr exon b2 or exon b3 to abl exon a2, resulting in either a b3a2 or a b2a2 gene fusion product. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:CMLVAX100
p210-B3A2-derived peptide vaccine



Previous:BayGam, BB-10901, BCG vaccine, bcr-abl (b2a2)-derived peptide vaccine, bcr-abl (b3a2)-derived peptide vaccine
Next:bcr-abl peptide vaccine, BEACOPP regimen, Bead Block Compressible Microspheres, becatecarin, Becenum

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov